Four Cases with FUS/CHOP Fusion Gene Products Positive Myxoid Liposarcoma Responding Effectively to Trabectedin Monotherapy
Hirohito Kirishi,Hiromichi Yamane,Nobuaki Ochi,Yusuke Sunada,Ayaka Mimura,Yoko Kosaka,Naruhiko Ichiyama,Tatsuyuki Kawahara,Yasunari Nagasaki,Hidekazu Nakanishi,Toshiyuki Kunisada,Nagio Takigawa
DOI: https://doi.org/10.2147/ott.s486163
IF: 4
2024-11-23
OncoTargets and Therapy
Abstract:Hirohito Kirishi, 1 Hiromichi Yamane, 1 Nobuaki Ochi, 1 Yusuke Sunada, 1 Ayaka Mimura, 1 Yoko Kosaka, 1 Naruhiko Ichiyama, 1 Tatsuyuki Kawahara, 1 Yasunari Nagasaki, 1 Hidekazu Nakanishi, 1 Toshiyuki Kunisada, 2 Nagio Takigawa 1 1 Department of General Internal Medicine 4, Kawasaki Medical School, Okayama, Japan; 2 Department of Medical Materials for Musculoskeletal Reconstruction, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan Correspondence: Hiromichi Yamane, Department of General Internal Medicine 4, Kawasaki Medical School, Okayama, Japan, Tel +81 86 225 2111, Fax +81 86 232 8343, Email Background: Myxoid liposarcoma, a rare type of tumor, accounts for approximately 30% of all liposarcomas. Myxoid liposarcomas harboring the FUS/CHOP fusion gene have shown promising results with trabectedin in basic research and some clinical experiments. However, the efficacy and safety of trabectedin in chemotherapy-naive soft tissue sarcomas or FUS/CHOP fusion gene-positive myxoid liposarcomas have not yet been established. Therefore, we evaluated the effectiveness and safety of trabectedin monotherapy in four cases of myxoid liposarcoma harboring the FUS/CHOP fusion gene at our hospital. Patients and Methods: We analyzed four patients with metastatic myxoid liposarcoma who underwent surgery at Okayama University and received chemotherapy at Kawasaki Medical School. These patients had positive test results for the FUS/CHOP fusion gene as an aid to pathological diagnosis by RT-PCR. RNA was extracted from tumor tissue sliced from frozen tumor specimens. Following reverse transcription, PCR was performed using TLS/FUS-CHOP primers. The resulting products were electrophoresed, and then the nucleotide sequences were confirmed. Case Presentation: Case 1: A 44-year-old male started trabectedin as second-line therapy after initial chemotherapy, which included doxorubicin. To date, he has completed 9 cycles, showing a response for 6 months. Case 2: A 71-year-old male, deemed intolerant to doxorubicin, started trabectedin as his first-line treatment. He has undergone 50 cycles to date, maintaining a response for 56 months. Case 3: A 59-year-old female began trabectedin as second-line therapy after initial chemotherapy, including doxorubicin. She responded for 6 months before experiencing disease progression. Case 4: A 79-year-old male developed new lesions after one course of initial chemotherapy, including doxorubicin. He then began trabectedin and has maintained a response for 10 months to date. Conclusion: Compared to other chemotherapies, trabectedin demonstrated potentially higher efficacy and a favorable safety profile for patients with myxoid liposarcoma harboring the FUS/CHOP fusion gene. Keywords: Trabectedin mono-therapy, efficacy, toxicity, myxoid liposarcoma Myxoid liposarcoma accounts for about 30% of liposarcomas, 1 which are rare cancers with an incidence rate of six or fewer cases per 100,000 people per year. 2 On the other hand, the FUS/CHOP fusion gene is formed by the translocation of the FUS gene located on the short arm of chromosome 16 (16p11.2) and the CHOP gene located on the long arm of chromosome 12 (12q13.3). The FUS/CHOP fusion gene products are presumed to be strongly associated with the development of myxoid liposarcoma as a tumor-specific transcription factor. 3 Among human soft tissue malignancies, approximately 95% of patients with myxoid liposarcoma, which commonly occurs in adults, are positive for the FUS/CHOP fusion gene. 4 Several reports suggest that trabectedin is expected to be effective against myxoid liposarcoma with the FUS/CHOP fusion gene, based on basic research into its mechanism of action. 5–8 Currently, it is used as a salvage chemotherapy after initial treatment, including doxorubicin, worldwide. 9 However, the role of trabectedin in the actual clinical treatment of untreated myxoid liposarcoma has not yet been established. 9 Since prospective clinical trials for rare diseases are challenging, it is meaningful to review and compile data on prognosis, safety, and efficacy from existing cases. Therefore, we examined and reported the efficacy and safety of trabectedin monotherapy in four patients with myxoid liposarcoma harboring the FUS/CHOP fusion gene at our hospital. We analyzed four patients with metastatic myxoid liposarcoma who underwent surgery at the Department of Medical Materials for Musculoskeletal Reconstruction, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences and received chemother -Abstract Truncated-
oncology,biotechnology & applied microbiology